SX-682 is a selective and potent antagonist of CXCR1/2 chemokine receptors that are expressed on both melanoma cells and MDSCs supporting tumor growth, immunosuppression and angiogenesis in response to CXCL1, CXCL2, or CXCL8 (147–149). Here, CXCL1 is linked to neoplasm.